Friday 6 November 2026 Export GTBP’s income statement to Excel — free account

GT Biopharma, Inc.

GTBP Healthcare Biotechnology

EPS: +98.9%
Free cash flow: −41.3%

Quarter to June 2026, against a year earlier

4.42 0.12 −2.64%

Follow GTBP

Alert me

Market cap: $9.4M
P/E: 0.8×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: −5138.41
Beneish M: n/a
Dividend safety: n/a

Overview

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(1,205.42%)	(1,674.31%)	(1,122.83%)	102.03%
ROA Full definition →		(554.30%)	(558.42%)	(585.46%)	(176.27%)
ROIC Full definition →		(1,746.37%)	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(1,023.60%)	(595.28%)	(488.68%)	(318.86%)
Free Cash Flow per Share Full definition →		(72.09)	(24.84)	(10.88)	(9.29)
Free Cash Flow Full definition →		(11.36)	(12.91)	(13.18)	(14.43)
Other line items
Cash ROIC Full definition →		(202.12%)	(101.75%)	(79.41%)	(167.30%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Interest Coverage Full definition →		—	—	(27.11)	(47.49)
Operating CF/Net income Full definition →		0.37	0.37	0.36	1.27
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(72.09)	(24.84)	(10.88)	(9.29)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026